Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$1.8 million.

  • Centessa Pharmaceuticals' Non Operating Income fell 14939.96% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 18268.0%. This contributed to the annual value of -$1.7 million for FY2024, which is 6892.04% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Non Operating Income of -$1.8 million as of Q3 2025, which was down 14939.96% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Non Operating Income registered a high of $5.4 million during Q2 2022, and its lowest value of -$4.0 million during Q4 2024.
  • In the last 4 years, Centessa Pharmaceuticals' Non Operating Income had a median value of -$878000.0 in 2023 and averaged -$131000.0.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Non Operating Income plummeted by 115428.57% in 2023, and later surged by 223246.75% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Non Operating Income (Quarter) stood at -$70000.0 in 2022, then plummeted by 1154.29% to -$878000.0 in 2023, then plummeted by 351.94% to -$4.0 million in 2024, then soared by 54.39% to -$1.8 million in 2025.
  • Its Non Operating Income stands at -$1.8 million for Q3 2025, versus $3.6 million for Q2 2025 and $1.0 million for Q1 2025.